Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, February 11 '25)

Image
By G.M.

 


    BMC Pediatr

  1. KUDLACEK M, Fromel K, Groffik D, Mitas J, et al
    Individual physical activity preferences of adolescents in the Czech Republic and Poland: a 14-year comparative study reflecting the gender trends and prospective responses to global lifestyle challenges.
    BMC Pediatr. 2025;25:98.
    PubMed         Abstract available


    J Infect Dis

  2. GOYA S, Wendm ST, Xie H, Nguyen TV, et al
    Genomic Epidemiology and Evolution of Rhinovirus in Western Washington State, 2021-2022.
    J Infect Dis. 2025;231:e154-e164.
    PubMed         Abstract available

  3. CHIME N, Anspach B, Jain V, Laajalahti O, et al
    Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
    J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093.
    PubMed         Abstract available

  4. BARZAGHI F, Visconti C, Pipitone GB, Bondesan S, et al
    Severe West Nile Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections in a Patient With Thymoma and Anti-Type I Interferon Antibodies.
    J Infect Dis. 2025;231:e206-e212.
    PubMed         Abstract available

  5. NAIR MS, Luck MI, Huang Y, Sabo Y, et al
    Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro.
    J Infect Dis. 2025;231:e68-e76.
    PubMed         Abstract available

  6. PISANIC N, Antar AAR, Hetrich MK, Demko ZO, et al
    Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution.
    J Infect Dis. 2025;231:121-130.
    PubMed         Abstract available

  7. LIN LY, Gantner P, Li S, Su B, et al
    Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines.
    J Infect Dis. 2024 Sep 20:jiae464. doi: 10.1093.
    PubMed         Abstract available

  8. BONOMO EJ, Shah M
    Rights-Based Legal Considerations for Tuberculosis Isolation Practices in Community Settings in the Postpandemic Era.
    J Infect Dis. 2025;231:31-36.
    PubMed         Abstract available

  9. BUTT AA, Yan P, Abou-Samra AB, Shaikh OS, et al
    COVID-19 Disease Incidence and Severity in Previously Infected Unvaccinated Compared with Previously Uninfected Vaccinated Persons.
    J Infect Dis. 2024 Oct 8:jiae484. doi: 10.1093.
    PubMed         Abstract available

  10. CHEW KW, McGinley B, Moser C, Li JZ, et al
    Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
    J Infect Dis. 2025;231:131-136.
    PubMed         Abstract available

  11. BABU TM, Jackson LA, El Sahly HM
    Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration.
    J Infect Dis. 2024 Oct 16:jiae504. doi: 10.1093.
    PubMed         Abstract available

  12. LORENZ N, James A, Van Rooyen T, Paterson A, et al
    Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic.
    J Infect Dis. 2025;231:e77-e81.
    PubMed         Abstract available

  13. DESCALZO MA, de Paula Junior FJ, Mallegas NV, Penayo E, et al
    Annual estimation of seasonal influenza burden in six South American countries: a retrospective analysis of SARInet surveillance data to inform policies.
    J Infect Dis. 2025 Feb 1:jiaf037. doi: 10.1093.
    PubMed         Abstract available

  14. JARA JH, Loayza S, Nogareda F, Couto P, et al
    Influenza vaccine averted illnesses in Chile, Guyana, and Paraguay during 2013-2018: a standardized approach to assess value of vaccination.
    J Infect Dis. 2025 Feb 1:jiaf038. doi: 10.1093.
    PubMed         Abstract available


    J Neurosurg Pediatr

  15. SALEH M, Lesha E, Nichols CS, Shimony N, et al
    A prospective observational study of operating room traffic during shunt surgery: who comes in and why?
    J Neurosurg Pediatr. 2024;35:167-173.
    PubMed         Abstract available


    J Virol

  16. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed         Abstract available


    Pediatrics

  17. MUKHOPADHYAY S, Kaufman DA, Saha S, Puopolo KM, et al
    Late-Onset Sepsis Among Extremely Preterm Infants During the COVID-19 Pandemic.
    Pediatrics. 2025 Jan 23:e2024067675. doi: 10.1542/peds.2024-067675.
    PubMed         Abstract available

  18. HE S, Esteban McCabe S, Conti RM, Volerman A, et al
    Prescription Stimulant Dispensing to US Children: 2017-2023.
    Pediatrics. 2025;155:e2024068558.
    PubMed         Abstract available


    PLoS Comput Biol

  19. LOMBARD B, Moultrie H, Pulliam JRC, van Schalkwyk C, et al
    Simulation-based validation of a method to detect changes in SARS-CoV-2 reinfection risk.
    PLoS Comput Biol. 2025;21:e1012792.
    PubMed         Abstract available


    PLoS Med

  20. BHATIA A, Preiss AJ, Xiao X, Brannock MD, et al
    Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
    PLoS Med. 2025;22:e1004493.
    PubMed         Abstract available

  21. RAGONNET R, Hughes AE, Shipman DS, Meehan MT, et al
    Estimating the impact of school closures on the COVID-19 dynamics in 74 countries: A modelling analysis.
    PLoS Med. 2025;22:e1004512.
    PubMed         Abstract available


    PLoS One

  22. GOYAL A, Saeed H, Sultan W, Singh A, et al
    Mortality trends and disparities for coexisting chronic obstructive pulmonary disease and cardiovascular disease: A retrospective analysis of deaths in the United States from 1999-2020.
    PLoS One. 2025;20:e0317592.
    PubMed         Abstract available

  23. BIBI N, Shah M, Khan S, Chohan MS, et al
    Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry.
    PLoS One. 2025;20:e0310855.
    PubMed         Abstract available

  24. WARNER BM, Vendramelli R, Boese AS, Audet J, et al
    Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection.
    PLoS One. 2025;20:e0316952.
    PubMed         Abstract available

  25. SCHUITEMA G, Lacchia A
    From anxiety to coping: Understanding psychological distance and coping skills for climate change and COVID-19 in 10-12-year-old children.
    PLoS One. 2025;20:e0317725.
    PubMed         Abstract available

  26. SYKES BL, Chavez EK, Strong JD
    Death and disappearance: Measuring racial disparities in mortality and life expectancy among people in state prisons, United States 2000-2014.
    PLoS One. 2025;20:e0314197.
    PubMed         Abstract available

  27. ZHANG C, Liu S, Qin M, Gao B, et al
    The dependency structure of international commodity and stock markets after the Russia-Ukraine war.
    PLoS One. 2025;20:e0316288.
    PubMed         Abstract available

  28. FISCHER B, Farr M, Gummert J, Knabbe C, et al
    High-frequency PCR-testing as a powerful approach for SARS-CoV-2 surveillance in the field of critical infrastructure: A longitudinal, retrospective study in a German tertiary care hospital.
    PLoS One. 2025;20:e0317009.
    PubMed         Abstract available

  29. COROCHER T, Edwards K, Hersusianto Y, Campbell D, et al
    Over-the-counter carrageenan-based sprays may interfere with PCR testing of nasopharyngeal swabs to detect SARS-CoV-2.
    PLoS One. 2025;20:e0316700.
    PubMed         Abstract available

  30. ALUSTA P, Paredes A, Azevedo M, Mullis L, et al
    Direct detection and identification of viruses in saliva using a SpecID ionization modified mass spectrometer.
    PLoS One. 2025;20:e0316368.
    PubMed         Abstract available

  31. KOSTIC K, Kostic A, Petrovic A, Vasilijevic A, et al
    The Serbian version of the Pandemic-Related Pregnancy Stress Scale (PREPS-SRB)-A validation study.
    PLoS One. 2025;20:e0317909.
    PubMed         Abstract available

  32. SAFDARI A, Keshav CS, Mody D, Verma K, et al
    The external validity of machine learning-based prediction scores from hematological parameters of COVID-19: A study using hospital records from Brazil, Italy, and Western Europe.
    PLoS One. 2025;20:e0316467.
    PubMed         Abstract available

  33. ARTOIS J, Vergne T, Fourtune L, Dellicour S, et al
    Spatial risk modelling of highly pathogenic avian influenza in France: Fattening duck farm activity matters.
    PLoS One. 2025;20:e0316248.
    PubMed         Abstract available

  34. FUNK M, Reinke M, Lowe B, Engelmann P, et al
    Development of an expectation management intervention for patients with Long COVID: A focus group study with affected patients.
    PLoS One. 2025;20:e0317905.
    PubMed         Abstract available

  35. SPITERI S, Salamon I, Girolamini L, Pascale MR, et al
    Surfaces environmental monitoring of SARS-CoV-2: Loop mediated isothermal amplification (LAMP) and droplet digital PCR (ddPCR) in comparison with standard Reverse-Transcription quantitative polymerase chain reaction (RT-qPCR) techniques.
    PLoS One. 2025;20:e0317228.
    PubMed         Abstract available

  36. GANDJOUR A
    Health-economic evaluation of the outpatient, inpatient, and public health sector in Germany: Insights from the first three COVID-19 waves.
    PLoS One. 2025;20:e0314164.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  37. LIAO Y, Ma H, Wang Z, Wang S, et al
    Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.
    Proc Natl Acad Sci U S A. 2025;122:e2406659122.
    PubMed         Abstract available


    Vaccine

  38. HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
    A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
    Vaccine. 2025;49:126780.
    PubMed         Abstract available

  39. GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
    Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
    Vaccine. 2025;49:126802.
    PubMed         Abstract available

  40. POWELL A, Jones A, Van Hout MC, Montgomery C, et al
    Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
    Vaccine. 2025;50:126837.
    PubMed         Abstract available

  41. SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
    A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
    Vaccine. 2025;50:126847.
    PubMed         Abstract available


    Virology

  42. POPOVIC ME, Tadic V, Popovic M
    (R)evolution of Viruses: Introduction to biothermodynamics of viruses.
    Virology. 2025;603:110319.
    PubMed         Abstract available

  43. YANG S, Yang X, Zhu W, Luo C, et al
    The novel COVID-19 treatment VV116 is a potential inhibitor of Zika virus.
    Virology. 2024;603:110334.
    PubMed         Abstract available

  44. ROY K, Saikia BK, Konwar R
    Exploring the role of carbon quantum dots as countermeasure for SARS-CoV-2 virus.
    Virology. 2025;603:110339.
    PubMed         Abstract available

  45. JONES LR
    Intra-host variability of SARS-CoV-2: Patterns, causes and impact on COVID-19.
    Virology. 2025;603:110366.
    PubMed         Abstract available

  46. CALDERON-PEREZ B, Nunez-Munoz LA, Trejo-Ayala LL, Rosales-Garcia VH, et al
    Immunogenicity of a multivalent protein subunit vaccine based on non-glycosylated RBD antigens of SARS-cov-2 and its variants.
    Virology. 2024;603:110380.
    PubMed         Abstract available

  47. ZHAO Y, Li W, Xu L, Tao Z, et al
    Antibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
    Virology. 2025;603:110404.
    PubMed         Abstract available

  48. MILLER JL, Niewiesk S
    Review of impaired immune parameters in RSV infections in the elderly.
    Virology. 2025;603:110395.
    PubMed         Abstract available

  49. ZHIRNOV OP, Chernyshova AI
    The uncleaved viral hemagglutinin HA0 increases influenza A virus resistance to thermal pasteurization.
    Virology. 2025;604:110389.
    PubMed         Abstract available


    Virus Res

  50. CHA RM, Park MJ, Baek YG, Lee YN, et al
    Genetic characteristics and pathogenesis of clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus isolated from poultry in South Korea, 2022-2023.
    Virus Res. 2025 Jan 31:199541. doi: 10.1016/j.virusres.2025.199541.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »